gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ETONHealthcarePharmaceuticals

Eton Pharmaceutcials, Inc. Common Stock (ETON)

$50.72−0.45%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$51.44▲ 186.41% in range
Nov 3, 2025Low $14.35 · High $64.43Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Eton Pharmaceutcials closed at $50.72 on Nov 4, down 0.45%, 21.3% below its 52-week closing high. Volume of 375.9K shares was 0.88× its 20-day average (close to normal).

Split-adjusted performance: -7.4% over one month, +68.2% over six months, +182.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $37.59M, up 98.6% from a year earlier, with a net margin of 30.8%.

Short interest was 1.9M shares at the Oct 15 settlement, up 6.0% from the prior report (7.6% of float, 3.3 days to cover).

Market cap$1.45B28.6M shares
Revenue · quarter$37.6M+98.6% YoY
Diluted EPS$0.35—
P/E · TTM114.3×P/S 13.7×
Net margin30.8%Gross 67.6%
Dividend yieldNone
52-week range14.35 – 64.43−21.3% from high
Volume375.9K0.88× 20-day avg
Volatility · 60d89.7%Annualised
Short % of float7.6%3.3 days to cover
Net cash-$1.1MCash $26.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.1%1M −7.4%3M +9.8%6M +68.2%YTD +199.9%1Y +182.4%3Y +1197.2%5Y +800.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum97
Revenue growth84
Net margin90
Value (low P/E)9
Size75

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short1.9M+6.0% vs prior
Days to cover3.3Settled Oct 15
% of float7.6%
Short vol. 10d67.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ETONEton Pharmaceutcials$50.72−0.45%+68.2%+98.6%30.8%114.3$1.45B
PCRXPacira BioSciences$36.40+0.03%+53.7%+6.2%2.4%99.2$1.45BCompare
KARDKardigan$15.56+8.66%————$1.45BCompare
RAPPRapport Therapeutics$25.93+1.93%−30.0%———$1.46BCompare
ANABAnaptysBio$47.51−0.46%−29.5%−8.0%−206.9%—$1.42BCompare
TYRATyra Biosciences$21.53+0.73%−36.3%———$1.48BCompare
DMRADamora Therapeutics$22.94+3.89%————$1.42BCompare
URGNUroGen Pharma$28.74−16.45%+9.5%+199.2%−19.8%—$1.40BCompare
MLYSMineralys Therapeutics$17.00+6.32%−43.6%———$1.50BCompare

News about Eton Pharmaceutcials

All news →
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?Zacks Investment Research · 2d agoNeutralETON Stock Surges 108% in Six Months: Here's What You Need to KnowZacks Investment Research · Oct 7, 2026▲ PositiveEton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare ConferenceGlobeNewswire Inc. · Aug 27, 2026▲ PositiveEton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001GlobeNewswire Inc. · Aug 5, 2026▲ PositiveEton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026GlobeNewswire Inc. · Aug 3, 2026▲ Positive

Quick answers

What does Eton Pharmaceutcials do?
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need.
What is ETON's market cap?
$1.45B, based on the Nov 4 close of $50.72.
What is ETON's P/E ratio?
114.3× trailing-twelve-month earnings of $12.69M.
Does Eton Pharmaceutcials pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ETON is sold short?
1.9M shares, 7.6% of float, as of Oct 15, 2026.
What sector is ETON in?
Healthcare, in the Pharmaceuticals industry.

About Eton Pharmaceutcials

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

HQ: Deer Park, IL44 employeesListed Nov 14, 2018etonpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology